The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Key Takeaways for Neratinib Plus T-DM1 Combination in Breast Cancer

Jame Abraham, MD
Published Online:7:16 PM, Mon February 11, 2019

Jame Abraham, MD, professor of medicine at the Cleveland Clinic and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses the key takeaways from the phase Ib study of trastuzumab emtansine (T-DM1) in combination with neratinib (Nerlynx) in patients with HER2-positive breast cancer.

First, Abraham says that the trial shows T-DM1 is an active regimen in combination with neratinib for patients who progress or are refractory to trastuzumab (Herceptin) and pertuzumab (Perjeta). With a dose of neratinib at 160 mg, the combination had deep responses in this patient population.

Additionally, there are correlative studies looking at patients who respond to neratinib, but more data is necessary to understand this, says Abraham. He also advises that physicians treating with neratinib be sure that their patients are using diarrhea prophylaxis.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.